e47.full. MS: Clinical Features, Neuroimaging, and Future Therapies: Monoclonal Antibodies. Current and Future Disease-Modifying Therapies in Multiple Sclerosis: Abstract and Introduction. Brain Imaging in Multiple Sclerosis. Degree of confidence The criteria of Fazekas et al resulted in the same sensitivity and specificity. These criteria require 3 lesions with 2 of the 3 following characteristics: infratentorial location, periventricular location, and lesion greater than 6mm. The criteria of Barkhof require 1 infratentorial lesion, 1 juxtacortical lesion, 3 periventricular lesions, and either 1 gadolinium-enhanced lesion or more than 9 lesions on T2-weighted MRI scans. These criteria resulted in a sensitivity of 73% and a specificity of 73%. Thus, as the MRI criteria become more stringent in the diagnosis of MS, specificity increases at the expense of decreasing sensitivity. Typical findings and pulse sequences Sagittal T1-weighted MRI depicts multiple hypointense lesions in the corpus callosum; this finding is characteristic of multiple sclerosis.
Axial T2-weighted MRI in a patient with multiple sclerosis demonstrates numerous white matter plaques in a callosal and pericallosal white matter distribution. MS Biomarkers in the Clinic: Around the Corner?: Biomarkers in the Clinic. Update on New Treatments, Clinical Aspects of MS, and Biomarkers: Abstracts and Insights From the 2011 European Meeting in MS. Focus on Emerging Therapies and Treatment Needs of MS Patients: Lessons Learned From the 2011 European Meeting on MS.